10-Q: IN8bio Q3 2025: Cash Dwindles, Clinical Progress Amid Doubts

IN8bio reports continued net losses and a dwindling cash position, raising substantial doubt about its ability to continue as a going concern, despite positive clinical data for INB-100 and INB-200.

Summary

• The company reported a net loss of $3.9 million for the three months ended September 30, 2025, a decrease from $7.1 million for the comparable prior year period.
• For the nine months ended September 30, 2025, the net loss was $14.5 million, down from $24.3 million for the same period in 2024.
• Cash and restricted cash totaled $10.962 million as of September 30, 2025, with cash alone at $10.689 million.
• Existing cash is only anticipated to fund projected operating expenses and capital expenditure requirements into June 2026, raising substantial doubt about the company's ability to continue as a going concern.
• Research and development expenses decreased to $2.1 million for the three months ended September 30, 2025, from $3.3 million in the prior year, and to $7.6 million for the nine months ended September 30, 2025, from $13.4 million in 2024.
• General and administrative expenses decreased to $1.9 million for the three months ended September 30, 2025, from $2.7 million in the prior year, and to $7.3 million for the nine months ended September 30, 2025, from $10.0 million in 2024.
• The INB-100 Phase 1 clinical trial for acute myeloid leukemia (AML) demonstrated 100% complete remission, progression-free survival (PFS), and overall survival (OS) rates at one-year post transplant for AML patients across both original and RP2D expansion cohorts, with a median follow-up of 20.1 months.
• The INB-200 Phase 1 clinical trial for newly diagnosed glioblastoma (GBM) showed a median PFS of 16.1 months for patients receiving repeated doses, a 133% increase over the expected 6.9 months for standard-of-care.
• Enrollment in the INB-400 Phase 2 clinical trial for newly diagnosed GBM was suspended in September 2024 to conserve cash resources, though preliminary data from treated patients showed a median PFS of 10.8 months.
• The company introduced the INB-600 T cell engager platform, with preclinical candidates INB-619 and INB-633 showing strong, antigen-specific cytotoxicity against leukemia cell lines and B cell depletion in Systemic Lupus Erythematosus (SLE) samples with minimal inflammatory cytokine release.
• A one-for-thirty reverse stock split was effected on June 5, 2025.
• The company raised approximately $8.5 million in net proceeds from its ATM program and $2.3 million from warrant exercises during the nine months ended September 30, 2025.

Sentiment

Score: 3

Explanation: While clinical data for INB-100 and INB-200 show promise and net losses decreased, the severe liquidity issues, explicit 'going concern' warning, and suspension of a Phase 2 trial due to cash constraints overshadow positive clinical updates. The short cash runway into June 2026 indicates significant financial instability.

Positives

• Net loss decreased significantly for both the three-month ($3.9 million vs $7.1 million) and nine-month ($14.5 million vs $24.3 million) periods ended September 30, 2025, compared to the prior year.
• INB-100 Phase 1 trial for AML demonstrated strong clinical outcomes with 100% complete remission, progression-free survival, and overall survival at one-year post transplant, exceeding real-world matched control groups.
• INB-200 Phase 1 trial for newly diagnosed GBM showed a median progression-free survival of 16.1 months for repeated doses, a 133% increase over the expected 6.9 months for standard-of-care, and surpassed historical median overall survival of 14.6 months.
• The new INB-600 T cell engager platform (INB-619, INB-633) shows promising preclinical data, including robust gamma-delta T cell expansion and targeted cytotoxicity with minimal inflammatory cytokine release, suggesting a favorable safety profile.
• Orphan Drug Designation was received for INB-400 (autologous and allogeneic) in April 2023, covering a broad range of malignant glioma indications.
• The company successfully raised $8.5 million in net proceeds through its ATM program and $2.3 million from warrant exercises during the nine months ended September 30, 2025.

Negatives

• There is substantial doubt about the company's ability to continue as a going concern, as existing cash is only anticipated to fund operations into June 2026.
• Enrollment in the INB-400 Phase 2 clinical trial for newly diagnosed GBM was suspended in September 2024 to conserve cash resources, delaying a key development program.
• The company has an accumulated deficit of $136.2 million as of September 30, 2025, reflecting recurring losses since inception.
• Cash preservation measures may impact the company's ability and timing to execute its strategy, including achieving anticipated milestones and data releases.
• Grade 1 and/or 2 Graft-versus-host disease (GvHD) was observed in approximately 60% of patients treated with INB-100, although it was responsive to steroid treatment.

Risks

• There is substantial doubt regarding the company's ability to continue as a going concern, requiring substantial additional funding.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to product candidates.
• A sale of a substantial number of common stock shares may cause the stock price to decline.
• Outstanding warrants may not be exercised, and the company may not receive any cash proceeds from their exercise.
• The company has incurred significant operating losses since inception and anticipates continued substantial operating losses, potentially never achieving or maintaining profitability.
• The ability to raise capital may be limited by applicable laws and regulations, such as the 'baby shelf rules' limiting offerings to one-third of public float if below $75.0 million.
• The company has a limited operating history and no products approved for commercial sale, making it difficult to evaluate future viability.
• The business is dependent on the successful clinical development, regulatory approval, and commercialization of its gamma-delta T cell product candidates.
• Interim, 'topline,' and preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification.
• DeltEx product candidates utilize novel approaches to cell therapies, presenting significant challenges in development, manufacturing, and commercialization.
• The clinical and commercial utility of the DeltEx platform is uncertain, and certain aspects of gamma-delta T cell function and production are poorly understood.
• Clinical product candidate development is a lengthy and expensive process with uncertain outcomes, potentially leading to additional costs and substantial delays.
• Difficulties in enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• The company may not be able to file investigational new drug (IND) applications on expected timelines, or the FDA may not permit trials to proceed.
• Development of a product candidate intended for use in combination with an already approved therapy may present increased complexity and challenges.
• Public opinion and scrutiny of cell-based immunotherapy and genetic modification approaches may impact public perception and business operations.
• The company faces significant competition from companies with substantially greater experience and resources.
• The manufacturing process is complex, and difficulties in production could delay or prevent sufficient supply of product candidates.
• Reliance on third-party contractors for manufacturing poses risks if they fail to adequately perform their obligations.
• Damage or loss to storage freezers and/or facilities from natural disasters or otherwise would cause delays.
• Dependence on a single third-party supplier for automated manufacturing devices and lentiviral vectors creates supply chain risk.
• Reliance on third-party healthcare professionals to administer gamma-delta T cells to patients carries risks of incorrect administration.
• Breach of license agreements with the University of Alabama at Birmingham Research Foundation, Children's Healthcare of Atlanta, Inc., and Emory University could lead to loss of intellectual property rights.
• Inability to obtain and maintain broad or robust patent protection for product candidates and technology could allow competitors to commercialize similar products.
• The ability to compete depends on attracting and retaining highly qualified personnel, with high dependence on co-founders William Ho and Dr. Lawrence Lamb.
• Actual or perceived failures to comply with data privacy and security obligations could lead to regulatory investigations, litigation, fines, and reputational harm.
• Maintaining compliance with the minimum required closing bid price for continued listing on the Nasdaq Capital Market is a risk.
• The reverse stock split may reduce and limit market trading liquidity and potentially have an anti-takeover effect.
• Unstable market and economic conditions, including inflation, interest rate volatility, bank closures, and geopolitical tensions, may adversely affect the business and share price.
• The business is exposed to potential product liability suits and other claims.
• Even if regulatory approvals are obtained, product candidates will remain subject to ongoing regulatory oversight.
• Approved product candidates may fail to achieve market acceptance by physicians, patients, or third-party payors.
• Inability to establish sales and marketing capabilities or enter into third-party agreements could hinder commercialization.
• Failure to obtain regulatory approval outside the United States would limit market opportunities.
• International operations carry various risks if products are commercialized abroad.
• Relationships with customers, physicians, and third-party payors are subject to federal and state healthcare fraud and abuse laws.
• Coverage and adequate reimbursement may not be available for product candidates, impacting profitability.
• Healthcare legislative reform measures may negatively impact the business and results of operations.
• The FDA's ability to review and approve new products may be hindered by various factors, including funding shortages or global health concerns.
• The ability to use net operating losses to offset future taxable income may be subject to certain limitations.
• Cash deposits in excess of federally insured limits expose the company to risk in case of bank failures.
• If research analysts do not publish research or publish unfavorable reports, the stock price and trading volume could decline.
• The company will continue to incur increased costs as a public company, and management will devote substantial time to compliance initiatives.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reporting or fraud.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult and prevent attempts to replace current management.
• The exclusive forum provision for disputes could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company's existing cash of $10.7 million as of September 30, 2025, is only anticipated to fund projected operating expenses and capital expenditure requirements into June 2026. Management plans to raise additional capital through equity and/or debt offerings, including ATM programs and private placements, and by identifying strategic collaborations, licensing, or other arrangements to support product candidate development. The company expects to incur additional losses in the future as it advances product candidates through clinical trials, expands its portfolio, and grows its clinical, regulatory, and quality capabilities.

Management Comments

• "We continue to deploy cash preservation measures to defer or reduce costs in the near term in order to preserve capital and increase financial flexibility given the ongoing market environment for biotechnology stocks."
• "These cash preservation measures may impact the Company's ability and the timing to execute its strategy. This includes the Company's ability to achieve anticipated milestones and the timing of data releases and/or regulatory filings for its preclinical and clinical programs."
• "To continue to fund the operations of the Company beyond this time period, management has developed plans, which primarily consist of raising additional capital through some combination of equity and/or debt offerings, including through ATM offerings and private placements of securities, and identifying strategic collaborations, licensing or other arrangements to support development of the Company's product candidates."
• "There is no assurance, however, that the Company will receive any proceeds from the exercise of these warrants or that any additional financing or any revenue-generating collaboration will be available when needed, that management of the Company will be able to obtain financing or enter into a collaboration on terms acceptable to the Company, or that any additional financing or revenue generated through third-party collaborations will be sufficient to fund the Company's operations through this time period."
• "If additional capital is not available on a timely basis, or at all, the Company will have to significantly delay, scale back or discontinue its research and development programs."

Industry Context

The company operates in the highly competitive immuno-oncology and cell therapy fields, positioning itself as the most clinically advanced gamma-delta T cell-focused company. Its DeltEx platform utilizes novel gamma-delta T cell technology, an emerging area. The company highlights its INB-600 platform's selective activation of gamma-delta T cells with minimal cytokine release syndrome (CRS), contrasting with traditional CD3-based T cell engagers that often induce CRS and T cell exhaustion. The filing also notes that competitor data presented at ASCO 2024 demonstrated persistence of donor-derived cells correlated with HLA matching, which supports IN8bio's approach in its INB-100 program.

Comparison to Industry Standards

• INB-100 AML patients demonstrated 100% PFS and 100% OS at one-year post transplant, significantly exceeding real-world matched control groups from the Center for International Blood and Marrow Transplant Research (CIBMTR) national database (67.8% PFS and 74.7% OS at one-year) and the Kansas University Cancer Center (KUCC) (57.4% PFS and 66.7% OS at one-year).
• INB-200 patients receiving repeated doses demonstrated a median PFS of 16.1 months, a +133% increase over the expected 6.9 months mPFS for the standard-of-care Stupp protocol in newly diagnosed GBM patients. These mPFS results have already surpassed the historical median OS of 14.6 months associated with the SOC Stupp protocol alone.
• INB-619 demonstrated complete B cell depletion comparable to commercially available CD3-based bi-specific T cell engagers but with a markedly improved cytokine release profile, showing minimal release of CRS associated cytokines (IL-6, IL-10, IL-4, and TNF-) even at higher concentrations.

Corporate Governance

Legal Proceedings

• The company is not currently party to any material legal proceedings.

Stakeholder Impact

• Shareholders face significant risk of dilution from future equity or convertible debt financings, as well as the potential for loss of investment due to the substantial doubt about the company's ability to continue as a going concern.
• Employees may experience uncertainty regarding job security and future compensation, particularly given the cash preservation measures and the suspension of a clinical trial.
• Patients involved in or awaiting clinical trials, especially for INB-400, may face delays or discontinuation of potential treatments due to funding constraints.
• Creditors face increased risk due to the company's precarious financial position and the explicit 'going concern' warning from independent auditors.

Next Steps

• Complete enrollment of the INB-100 expansion cohort by year-end 2025 or early 2026.
• Anticipate long-term follow-up results for the INB-100 expansion cohort in 2026.
• Provide additional updates for INB-200 and INB-400 at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting in November 2025.
• Present additional preclinical data for the INB-600 platform in the second half of 2025 and in 2026.
• Seek additional funding sources, potential accelerated approval pathways, and/or strategic opportunities to partner the INB-400 program.
• Advance clinical development of INB-100 and progress other product candidates, including the preclinical pipeline.
• Strengthen internal research and development capabilities.
• Actively seek additional funding and potential collaborative partners for INB-100, INB-400, INB-619, and INB-633.

Key Dates

Recommendation

The 'substantial doubt about the company's ability to continue as a going concern' is a critical red flag that overrides any positive clinical data. With cash only projected to last until June 2026 and a Phase 2 trial already suspended due to funding, the financial instability is severe. The risk of significant dilution from future financings is high, and the potential for shareholders to lose their entire investment is explicitly stated. A seasoned investor would prioritize capital preservation and exit the position given the severe liquidity risk and operational uncertainty.

Keywords

Gamma-delta T cell, Immunotherapy, Oncology, Glioblastoma, Acute Myeloid Leukemia, Cell Therapy, Clinical Trials, Biopharmaceutical, INB-100, INB-200, INB-400, INB-600, DeltEx platform, SEC filing, 10-Q, Financial results, Going concern, Capital raise, Stock split, Nasdaq